Targets › APOE
1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Nov 2028.
APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids. APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance. (UniProt, P02649)
Open in Phaseline: the race on APOE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Lexeo Therapeutics | LX1001 (AAVrh.10hAPOE2) Gene therapy delivering human APOE2 via adeno-associated virus serotype rhesus 10 | APOE | Phase 1 | Alzheimer Disease | Nov 2028 |
Alzheimer Disease (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.